Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to investigate the safety and tolerability of a multiple dose 7 day once-daily treatment of BAY 1067197 versus a 7 day treatment of placebo in patients with chronic systolic heart failure, determined by the incidence and severity of adverse clinical events, new laboratory and electrocardiographic abnormalities and to investigate the pharmacokinetics of a 7 day treatment with BAY 1067197 in patients with chronic systolic heart failure
Critère d'inclusion
- Chronic systolic heart failure